TCR & CAR Engineered T-Cell and NK Cell Therapeutics Discussed in La Merie Publishing Report Available at MarketPublishers.com
30 Aug 2016 • by Natalie Aster
LONDON – The results of anti-CD19 CAR T-cell therapy were early and very impressive, and they are expected to see confirmation of pivotal studies in ALL and NHL that are currently ongoing, and the approval is likely to take place in 2017.
Big Pharma and money poured by private financing rounds, partnering money and public offerings encourage the race among Juno Therapeutics, Novartis and Kite Pharma each of whom eager to become the first one bringing its own autologous CD19 CAR T-cell products.
TCR target discovery and gene editing emerge to be key technologies. Players that have these capabilities will have a very strong position in corporate development, partnering and financing.
There are also some hurdles in this space that players face, such as protocol issues, deficiency of strictly tumor-specific targets, and more.
In-demand research report “TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016” elaborated by La Merie Publishing offers an up-close look at the therapeutic landscape related to TCR & CAR Engineered T-Cells and NK Cells. The study starts with detailed coverage of company financing: it looks at partnering deals, the stocks market, early stage financing, etc.
The report delves deep into the business development and covers licensing issues in detail. The research study explores improvements in the therapeutic field and focuses on the competitive environment. Company profiles and cell therapy profiles can be found in the research report, too. Information on business opportunities is also available in the study.
Other Markets Covered by La Merie Publishing Include:
- Biosimilar and Biosuperior Anti-TNF Antibodies
- CD19-Targeted Therapeutics
- Flavivirus Vaccines
- Inhibitors of the bromodomain and extra-terminal domain (BET) family
More cutting-edge reports by the publisher can be found at its page.